


CLAIM AMENDMENTS


Cancel claims 1-80.

81. (Currently Amended) ~~The A~~ A compound of the formula




~~claim 22~~, wherein R₄ and R₅ together form cyclohexyl.

82. (Currently Amended) ~~The A~~ A compound of the formula



claim 6, wherein R₁ is aralkyl, arylheterocyclylalkyl, alkylaminocarbonyl, alkenylaminocarbonyl, arylaminocarbonyl, alkoxyalkyl, aryloxyalkyl, or aralkoxyalkyl, wherein the aryl portion is phenyl or naphthyl and the alkyl portion is a C₁-C₆ alkyl, and the heterocyclyl is a 3-7 membered ring having at least one of N, O, and S; R₂ is dicarboxyalkyl, R₃ is carboxyalkyl, R₄ and R₅ together form cycloalkyl, and R₆ is a C₂-C₄ alkenylenyl group.

83. (Currently Amended) The compound of claim 82, which has the formula:



84. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically or pharmacologically acceptable carrier and a compound of ~~any of claims 81-83~~ claim 81.

85. (Currently Amended) A method for inhibiting an SH2 domain from binding with a phosphoprotein comprising contacting an SH2 domain with a compound of ~~any of claims 81-83~~ claim 81.

86. (Currently Amended) A method for preventing or treating a disease, state, or condition in a mammal comprising administering a compound of ~~any of claims 81-83~~ claim 81.

87. (Currently Amended) A method for inhibiting cell motility or angiogenesis in a mammal comprising administering to said mammal a compound of ~~any of claims 81-83~~ claim 81.

88. (Canceled)

89. (Canceled)
90. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 82.
91. (New) A method for inhibiting an SH2 domain from binding with a phosphoprotein comprising contacting an SH2 domain with a compound of claim 82.
92. (New) A method for preventing or treating a disease, state, or condition in a mammal comprising administering a compound of claim 82.
93. (New) A method for inhibiting cell motility or angiogenesis in a mammal comprising administering to said mammal a compound of claim 82.
94. (New) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of claim 83.
95. (New) A method for inhibiting an SH2 domain from binding with a phosphoprotein comprising contacting an SH2 domain with a compound of claim 83.
96. (New) A method for preventing or treating a disease, state, or condition in a mammal comprising administering a compound of claim 83.
97. (New) A method for inhibiting cell motility or angiogenesis in a mammal comprising administering to said mammal a compound of claim 83.